Tirzepatide for treating scarring hair loss (CCCA)
Treatments studied
Part of Hormones & metabolism, Skin clinical trials.
This study tests whether tirzepatide (Mounjaro) can help treat a specific type of scarring hair loss called CCCA. It is for people whose hair loss is still active and who are not taking diabetes or weight-loss medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with a type of scarring hair loss called CCCA (central centrifugal cicatricial alopecia).
- Your hair loss is still active and not stable or resolved.
- You have not used any treatment for CCCA in the last 6 weeks.
- You are not taking any medicine for diabetes or weight loss.
- You do not have a personal or family history of medullary thyroid cancer.
- You are willing to be followed by a doctor at Johns Hopkins for the whole study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This trial is testing a medication called tirzepatide (Mounjaro) to see if it can help people with a rare fat disorder called familial partial lipodystrophy. The study hopes to improve blood sugar control and lower triglycerides, which are often high in this condition.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
This study tests whether the weight-loss drug tirzepatide (Mounjaro) can help prevent breast cancer from coming back in people who are overweight and have a sign of leftover cancer cells in their blood (called MRD-positive). You must have already finished at least one year of hormone therapy for early-stage breast cancer.
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
This trial studies tirzepatide to see if it can slow the progression of coronary artery plaque in people with type 2 diabetes. It uses special heart CT scans to track changes over time.
Hear when a new Central Centrifugal Cicatricial Alopecia (CCCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.